Share issue
October 2026
Oncopeptides completes a directed share issue of approximately SEK 100 million
October 13, 2026 – Regulatory press releaseThe Board of Directors of Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, has resolved to issue 50,000,000 new ordinary shares (the “New Shares”) in a directed share issue to Swedish and international institutional investors, pursuant to the authorisation granted by the Annual General Meeting held on 21 May 2026 (the “Directed Share Issue”). The subscription price has been set at SEK 2.00 per New Share, and the Directed Share Issue will provide the Company with proceeds of SEK 100 million before transaction costs.
Oncopeptides intends to carry out a directed share issue of approximately SEK 100 million
October 13, 2026 – Regulatory press releaseOncopeptides AB (publ) (“Oncopeptides” or the “Company”) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces its intention to carry out a directed share issue of approximately SEK 100 million to Swedish and international institutional investors through an accelerated bookbuilding procedure (the “Directed Share Issue”). The Company intends to use the net proceeds to carry out the CMC activities required ahead of the next clinical development phase, complete preparations for clinical study start, and finance the execution of this phase within the Company’s glioblastoma programme. The Directed Share Issue aims to maintain the pace of development and enable the programme to reach an important clinical milestone.